AFP Planvital (XSGO:PLANVITAL) Research & Development: CLP0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSGO:PLANVITAL AFP Planvital SA XSGO:PLANVITAL
94 GF Score
Price CLP260.47
GF Value CLP228.13
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is AFP Planvital Research & Development?

AFP Planvital XSGO:PLANVITAL 94 Research & Development is CLP0 Mil as of Jun. 2026. GuruFocus rates XSGO:PLANVITAL with a GF Score™ of 94/100 and a GF Value™ of CLP228.13 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. AFP Planvital's Research & Development for the three months ended in Jun. 2026 was CLP0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was CLP0 Mil.

AFP Planvital  (XSGO:PLANVITAL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

AFP Planvital Research & Development Related Terms

AFP Planvital Research & Development Historical Data

* Premium members only.

The historical data trend for AFP Planvital's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFP Planvital Research & Development Chart

AFP Planvital Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AFP Planvital Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSGO:PLANVITAL
94GF Score
AFP Planvital SA XSGO:PLANVITAL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFP Planvital Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CLP0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CLP0 Mil mean?
AFP Planvital (XSGO:PLANVITAL) has a Research & Development of CLP0 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on AFP Planvital and its competitors.
Is AFP Planvital's Research & Development too high?
AFP Planvital's current Research & Development is CLP0 Mil. Overall, AFP Planvital has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AFP Planvital's Research & Development compare to BLK and BX?
AFP Planvital's Research & Development of CLP0 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Asset Management company?
A good Research & Development depends on the Asset Management industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on AFP Planvital and its competitors. AFP Planvital's current Research & Development is CLP0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFP Planvital stock overvalued right now?
Based on GuruFocus' analysis, AFP Planvital (XSGO:PLANVITAL) is currently considered Modestly Overvalued. The stock's GF Value™ is CLP228.13, compared to a current price of CLP260.47 — trading 14.2% above its estimated fair value. The current Research & Development is CLP0 Mil. AFP Planvital's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For AFP Planvital (XSGO:PLANVITAL), the current Research & Development is CLP0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFP Planvital (XSGO:PLANVITAL) Overvalued in 2026?

Based on GuruFocus' analysis, AFP Planvital stock appears to be overvalued. The current stock price of CLP260.47 is trading 14.2% above its estimated GF Value™ of CLP228.13. GuruFocus considers AFP Planvital to be Modestly Overvalued.

Key valuation signals for XSGO:PLANVITAL:

  • Research & Development: CLP0 Mil
  • GF Value™: CLP228.13 vs. price of CLP260.47 (14.2% above fair value)
  • GF Score™: 94/100 with 2 warning signs

No single metric tells the full story. See the XSGO:PLANVITAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AFP Planvital Business Description

Address Tenderini 127, Santiago, CHL
AFP Planvital SA is a Chile-based pension fund administrator. Its activities include investment & collection of affiliate contributions, management of individual capitalization accounts, & provision of life & disability benefits, as well as retirement pensions. It offers professional pension management.
94GF Score

Get the complete analysis for XSGO:PLANVITAL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CLP260.47
Price
CLP228.13
GF Value